Can I Take Folate with Egrifta (Tesamorelin)?

What Is Tesamorelin and Why Does Folate Come Up?

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). Injected subcutaneously once daily at 2 mg, it stimulates pituitary somatotrophs to secrete growth hormone (GH), which in turn raises insulin-like growth factor-1 (IGF-1) and drives visceral fat reduction in adults with HIV-associated lipodystrophy. The FDA first approved tesamorelin under the brand name Egrifta in 2010, with a reformulated version (Egrifta SV) approved in 2019 [1].

Folate is a water-soluble B-vitamin that drives one-carbon transfer reactions throughout the body. These reactions include DNA synthesis, DNA methylation, and the remethylation of homocysteine to methionine [2]. Patients with HIV frequently show low serum folate due to malabsorption, dietary insufficiency, and drug interactions with agents such as trimethoprim-sulfamethoxazole [3].

The question of co-administration arises because many HIV patients on Egrifta also take multiple supplements or have been tested for MTHFR gene variants, which affect how efficiently folate is processed.

How Tesamorelin Works at the Receptor Level

Tesamorelin binds GHRH receptors on pituitary somatotrophs with an affinity comparable to endogenous GHRH(1-44). Binding triggers adenylyl cyclase activation, cyclic AMP accumulation, and pulsatile GH release [4]. GH then acts on hepatic and peripheral receptors to stimulate IGF-1 synthesis. This entire cascade is peptide-receptor-mediated and does not require folate cofactors at any documented step [1][4].

How Folate Is Metabolized

Dietary folic acid is reduced by dihydrofolate reductase (DHFR) to dihydrofolate and then to tetrahydrofolate (THF). The enzyme MTHFR converts 5,10-methyleneTHF to 5-methylTHF, which is the primary circulating form and the methyl donor for homocysteine remethylation [2]. Individuals carrying the MTHFR C677T variant show 30 to 70% reduced enzyme activity, depending on genotype, which can raise plasma homocysteine and reduce methylation capacity [5].

Neither the GHRH receptor pathway nor the GH/IGF-1 axis appears anywhere in the folate metabolic network described in current biochemistry literature [2][5].

Is There a Pharmacokinetic Interaction?

No pharmacokinetic (PK) interaction between folate and tesamorelin has been identified in the published literature or the current Egrifta SV prescribing information [1].

Absorption and Distribution

Tesamorelin is a 44-amino-acid peptide administered subcutaneously. It is not absorbed orally and does not transit the gastrointestinal system in a way that would compete with folate absorption in the small intestine [1]. Folate is absorbed predominantly in the jejunum via proton-coupled folate transporter (PCFT/SLC46A1) and reduced folate carrier (RFC/SLC19A1) [6]. These transporters have no known affinity for peptide hormones.

Metabolism

Tesamorelin is degraded by ubiquitous dipeptidyl peptidase IV (DPP-IV) and by general plasma peptidases, with a plasma half-life of approximately 26 minutes [1]. Folate metabolism occurs intracellularly through DHFR, MTHFR, methionine synthase, and related enzymes [2]. The two metabolic routes share no common enzymes.

Protein Binding and Renal Clearance

Tesamorelin plasma protein binding has not been fully characterized, but peptide hormones of this class are not expected to displace folate from its transport proteins. Folate circulates loosely bound to albumin and specifically to folate-binding protein [6]. No displacement interaction is expected or documented [1].

Is There a Pharmacodynamic Interaction?

No pharmacodynamic (PD) interaction has been reported, but understanding each drug's downstream effects helps clarify why monitoring certain labs still makes sense.

GH Axis and Glucose Metabolism

Tesamorelin raises IGF-1 and may modestly increase fasting glucose or worsen insulin resistance in susceptible patients. In the key phase 3 trials (N=816 combined), Egrifta produced a statistically significant increase in fasting glucose compared with placebo (mean difference approximately 4.3 mg/dL, P<0.001) [7]. Folate supplementation, at doses of 400 to 5,000 mcg/day, has not been shown to materially alter insulin sensitivity or glucose homeostasis in randomized controlled trials [8].

Homocysteine and Cardiovascular Risk in HIV

Elevated homocysteine is independently associated with cardiovascular disease, a concern already heightened in people living with HIV [9]. Tesamorelin itself does not appear to raise homocysteine. Folate supplementation at 0.8 to 1 mg/day reduces plasma homocysteine by roughly 25% based on a Cochrane meta-analysis of 13 randomized trials [10]. This effect may be cardiovascularly favorable for HIV patients on Egrifta, though no trial has directly tested this combination.

Methylation and IGF-1 Gene Expression

One theoretical question is whether impaired methylation in MTHFR-variant patients could alter IGF-1 gene promoter methylation and thereby blunt the Egrifta response. This question has not been tested in a dedicated clinical trial. Available evidence does not support a clinically meaningful PD interaction at therapeutic folate doses.

MTHFR Variants: Who Needs Extra Attention?

MTHFR variants are found in approximately 10 to 15% of individuals of Northern European ancestry for the homozygous C677T genotype, and the variant is also prevalent in Latin American populations [5]. HIV cohorts carry these variants at background population frequencies, meaning a meaningful portion of people on Egrifta may have reduced folate processing capacity.

Clinical Implications of Reduced MTHFR Activity

Reduced MTHFR activity results in lower 5-methylTHF availability, elevated homocysteine, and potentially reduced SAM-dependent methylation reactions [5]. In practice this translates to a preference for the active form, 5-methyltetrahydrofolate (5-MTHF, sold as Metafolin or Quatrefolic), over synthetic folic acid in MTHFR-positive individuals [11]. Synthetic folic acid must be converted through DHFR before entering the folate cycle; 5-MTHF bypasses this step entirely [11].

Does MTHFR Status Change the Egrifta Decision?

No. MTHFR status does not affect tesamorelin dosing, efficacy, or tolerability based on current data. It does affect which form of folate is preferable if supplementation is needed. A prescriber evaluating an Egrifta patient with confirmed MTHFR C677T homozygosity may reasonably choose 5-MTHF at 400 to 1,000 mcg/day over standard folic acid [11][5].

Folate Depletion Risks in People Living with HIV on Multiple Medications

HIV therapy rarely consists of a single agent. Many patients on Egrifta concurrently take trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis prophylaxis, metformin for glucose management, or anticonvulsants for neuropathy.

Trimethoprim-Sulfamethoxazole

TMP-SMX inhibits dihydrofolate reductase in human cells at clinical doses, reducing the conversion of dietary folate to its active forms [3]. A 2003 review in Clinical Infectious Diseases confirmed that long-term TMP-SMX use can produce macrocytic anemia and hyperhomocysteinemia in HIV patients, effects partially reversible with folate supplementation [3]. Patients on both Egrifta and TMP-SMX should have serum folate and a complete blood count checked at baseline and every 6 months.

Metformin

Metformin impairs vitamin B12 absorption via ileal calcium-dependent mechanisms and may modestly impair folate status over long durations [12]. Because Egrifta-related hyperglycemia may prompt metformin co-prescription, awareness of this interaction is practical. The American Diabetes Association recommends periodic B12 monitoring in patients on long-term metformin, and folate levels merit inclusion in this panel [13].

Anticonvulsants

Phenytoin, carbamazepine, and valproic acid all reduce serum folate through induction of hepatic cytochrome P450 enzymes and possibly direct inhibition of intestinal folate absorption [14]. Patients on Egrifta who also require anticonvulsants for HIV-related neuropathy should have folate status assessed, and supplementation at 1 mg/day may be appropriate after physician review [14].

Recommended Monitoring Panel for Patients Taking Egrifta with Folate

The following monitoring framework applies to adults taking tesamorelin 2 mg SC daily who are also supplementing with folate (any form).

Baseline Labs (Before Starting or Adding Folate)

• Serum folate and red blood cell (RBC) folate
• Plasma homocysteine
• Serum B12 (folate metabolism is B12-dependent; deficiency can mask with high-dose folic acid)
• IGF-1 (to establish Egrifta response baseline)
• Fasting glucose and HbA1c (Egrifta carries a glucose signal)
• Complete blood count (to detect macrocytosis)

Follow-Up Labs at 3 Months

• Repeat IGF-1 (Egrifta target is upper half of age-adjusted normal range per FDA label) [1]
• Repeat fasting glucose
• Repeat homocysteine if elevated at baseline

Follow-Up Labs at 6 Months and Annually

• Serum and RBC folate
• Plasma homocysteine
• Serum B12
• IGF-1
• Fasting glucose and HbA1c
• CBC with differential

There is no required dose-separation window between folate and tesamorelin. Because tesamorelin is a subcutaneous injection administered at a fixed time each day and folate is taken orally, the two are inherently separated by route and are absorbed through completely different mechanisms [1][6].

Dosing Guidance for Folate in Egrifta Patients

Standard supplemental folate for adults without a documented deficiency is 400 mcg/day as folic acid or 400 mcg/day as 5-MTHF [15]. Patients with MTHFR C677T homozygosity, documented deficiency, or concurrent DHFR-inhibiting medications (TMP-SMX) may need 800 to 1,000 mcg/day of 5-MTHF [11][5].

Doses above 1 mg/day of folic acid require a prescription in some jurisdictions and carry the theoretical risk of masking vitamin B12 deficiency by correcting macrocytosis while neurological damage progresses [15]. This concern is particularly relevant in older HIV patients and those with malabsorption. Always confirm B12 status before starting folate above 800 mcg/day [15].

Forms of Folate: Which to Choose

• Folic acid (synthetic): cheapest, widely available, adequate for most people with normal MTHFR function.
• 5-Methyltetrahydrofolate (5-MTHF, Metafolin, Quatrefolic): preferred for MTHFR C677T or A1298C carriers; bypasses DHFR conversion [11].
• Folinic acid (leucovorin): used clinically to rescue from DHFR inhibition (e.g., methotrexate toxicity); not a standard supplement choice for most Egrifta patients but may be considered with high-dose TMP-SMX [3].

What to Tell Your Prescriber

Before starting folate alongside Egrifta, inform your prescriber of:

1. All current antiretroviral agents (some affect B12 and folate secondarily)
2. TMP-SMX use, current or recent
3. Any anticonvulsant therapy
4. History of macrocytic anemia or B12 deficiency
5. Known MTHFR genotype, if tested

What Clinicians and Guidelines Say

The Egrifta SV prescribing information does not list folate or any B-vitamin as a contraindicated or interacting supplement, and the label's drug interaction section focuses on CYP450-metabolized medications, which folate is not [1].

The American Academy of HIV Medicine has stated that nutritional co-morbidities, including folate and B12 insufficiency, are "frequently underdiagnosed in people living with HIV and should be screened for during routine care" [16]. This guidance applies regardless of whether the patient is on Egrifta.

A 2019 paper in the Journal of Acquired Immune Deficiency Syndromes reviewing micronutrient status in 312 HIV-positive adults found that 28% had serum folate below the normal reference range and 41% had elevated homocysteine, underscoring how common this nutritional gap is in the exact population prescribed tesamorelin [17].

The Natural Medicines Database classifies the folate-tesamorelin combination as having no known interaction, placing it in its lowest interaction-concern category. No dose adjustment or specific precaution is flagged [18].

Practical Summary for Patients and Clinicians

Folate does not interfere with how tesamorelin is absorbed, distributed, metabolized, or excreted. It does not antagonize or mimic the GHRH receptor. Taking folate at standard supplemental doses will not reduce the visceral fat benefit of Egrifta or alter IGF-1 response based on current evidence.

The practical case for monitoring comes not from a drug-supplement interaction but from the clinical context: HIV patients on multiple medications are at higher baseline risk for folate depletion, elevated homocysteine, and macrocytic anemia. Adding structured lab surveillance at the intervals above is a reasonable way to manage that risk without changing the Egrifta regimen.

Patients already taking both tesamorelin and folate do not need to stop either. They should confirm their folate form choice with their prescriber if they carry MTHFR variants, and they should ensure B12 is checked before any dose of folate above 800 mcg/day is continued long-term.